Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D07BVI
|
||||
| Former ID |
DAP001561
|
||||
| Drug Name |
Ipilimumab
|
||||
| Synonyms |
BMS-734016; MDX-010; MDX-101; Yervoy (TN)
|
||||
| Drug Type |
Antibody
|
||||
| Indication | Late-stage melanoma; Prostate cancer [ICD9: 172, 185; ICD10:C43, C61] | Approved | [1], [2], [3] | ||
| Company |
Bristol-Myers Squibb
|
||||
| CAS Number |
CAS 477202-00-9
|
||||
| SuperDrug ATC ID |
L01XC11
|
||||
| Target and Pathway | |||||
| Target(s) | Cytotoxic T-lymphocyte protein 4 | Target Info | [1] | ||
| KEGG Pathway | Cell adhesion molecules (CAMs) | ||||
| T cell receptor signaling pathway | |||||
| Autoimmune thyroid disease | |||||
| Rheumatoid arthritis | |||||
| Pathway Interaction Database | Calcineurin-regulated NFAT-dependent transcription in lymphocytes | ||||
| Reactome | CTLA4 inhibitory signaling | ||||
| WikiPathways | Vitamin D Receptor Pathway | ||||
| T-Cell Receptor and Co-stimulatory Signaling | |||||
| Allograft Rejection | |||||
| Costimulation by the CD28 family | |||||
| References | |||||
| REF 1 | Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5. | ||||
| REF 2 | 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4. | ||||
| REF 3 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6888). | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.